| Literature DB >> 25115172 |
Salvatore Pisu1, Giovanni Caocci, Ernesto d'Aloja, Fabio Efficace, Adriana Vacca, Eugenia Piras, Maria Grazia Orofino, Carmen Addari, Michela Pintor, Roberto Demontis, Federica Demuru, Maria Rita Pittau, Gary S Collins, Giorgio La Nasa.
Abstract
INTRODUCTION: The informed consent process is the legal embodiment of the fundamental right of the individual to make decisions affecting his or her health., and the patient's permission is a crucial form of respect of freedom and dignity, it becomes extremely important to enhance the patient's understanding and recall of the information given by the physician. This statement acquires additional weight when the medical treatment proposed can potentially be detrimental or even fatal. This is the case of thalassemia patients pertaining to class 3 of the Pesaro classification where Allogenic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment. Unfortunately, this kind of intervention is burdened by an elevated transplantation-related mortality risk (TRM: all deaths considered related to transplantation), equal to 30% according to published reports. In thalassemia, the role of the patient in the informed consent process leading up to HSCT has not been fully investigated. This study investigated the hypothesis that information provided by physicians in the medical scenario of HSCT is not fully understood by patients and that misunderstanding and communication biases may affect the clinical decision-making process.Entities:
Mesh:
Year: 2014 PMID: 25115172 PMCID: PMC4136633 DOI: 10.1186/1747-5341-9-13
Source DB: PubMed Journal: Philos Ethics Humanit Med ISSN: 1747-5341 Impact factor: 2.464
Patient features
| 21 (16-37) | | |
| Median recipient age (years, range) | ||
| Gender | | |
| Male | 16/34 | 47 |
| Female | 18/34 | 53 |
| Death | 9/34 | 27 |
| Rejection | 0 | 0 |
| Grade II-IV acute GVHD (in dead pts) | 6/9 | 67 |
| Grade II-IV acute GVHD (in live pts) | 3/25 | 12 |
| Chronic GVHD | 3/25 | 12 |
| Gender | | |
| Male | 12/25 | 48 |
| Female | 13/25 | 52 |
| Median test age (years, range) | 25 (18-35) | |
| ≤ 20 | 13 | 52 |
| ≥ 20 | 12 | 48 |
| School level at the time of HSCT | | |
| High | 14/25 | 56 |
| Low | 11/25 | 44 |
GVHD: Graft Versus Host Disease.
Communication factors explored among patients and physicians
| 1 | Transplant-related mortality risk perception (1 to 7 Likert Scale) |
| 2 | Percent value of mortality risk communicated and recalled (% value from 5% to 50%) |
| 3 | Percent value of mortality risk considered acceptable to undergo the transplant procedure (% value from 5% to 50%) |
| 4 | Perception of GVHD risk as a life-threatening condition (1 to 7 Likert Scale) |
| 5 | How much previous information (other patients, friends, TV, Internet) had influenced the patient before informed consent (1 to 7 Likert Scale) |
| 6 | Motivation to undergo HSCT before informed consent (1 to 7 Likert Scale) |
GVHD: Graft Versus Host Disease.
Differences between patients and physicians perceptions
| Transplant-related mortality risk perception | 4,9 | 3.6 | |
| (1 to 7 Likert Scale) | (0,3) | (0.2) | |
| Percent value of mortality risk communicated and recalled | 30.0 | 20.4 | |
| (% value from 5% to 50%) | (2.6) | (1.4) | |
| Percent value of mortality risk considered acceptable to undergo the transplant procedure | 19.6 | 29.6 | |
| (% value from 5% to 50%) | (2.5) | (2.2) | |
| Perception of GVHD as a severe life-threatening condition | 5.4 | 4.1 | |
| (1 to 7 Likert Scale) | (0.4) | (0.2) | |
| How much previous information had influenced the patient before informed consent | 4.6 | 2.2 | |
| (1 to 7 Likert Scale) | (0.4) | (0.3) | |
| Motivation to undergo HSCT before informed consent | 4.6 | 4.8 | |
| (1 to 7 Likert Scale) | (0.5) | (0.3) |
*Two-tailed t test significant value; GVHD: Graft Versus Host Disease; SE: standard error.